Plain-English translation of NCT03770923 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Rheumatoid arthritis causes painful joint inflammation that can get worse over time. This study is testing whether two medications — and — which are typically used to treat allergies and inflammation, might also help reduce rheumatoid arthritis symptoms. Researchers want to see if these medications can improve how patients feel and reduce disease activity.
Standard rheumatoid arthritis treatments don't work well for everyone, and some patients experience side effects or don't get enough relief. This study explores whether these allergy and inflammation medications might offer another option to help control the disease.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of three groups: taking once daily, taking once daily, or receiving no special medication. You'll take your assigned medication (or none) and return for visits where researchers will check how your arthritis is responding and monitor your health. The study involves 75 participants total, and your commitment would include regular check-ins to assess your symptoms and disease activity.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Egypt
Phase
Large-scale testing
Sponsor
Sherief Abd-Elsalam
Enrollment target
~75 participants
Started
October 2018
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2018.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sherief Abd-Elsalam, Ph D
Head of Clinical Pharmacy Department
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.